巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Exelixis

    EXEL
    16.180
    0.290
    1.79%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Exelixis - 延遲價格・最後更新於 28/09 8:28
    最高位
    16.340
    最低位
    16.020
    開市價
    --
    前收市價
    15.895
    成交量(千)
    105.32
    成交額(百萬)
    12.79
    買入
    12.900
    賣出
    19.080
    每手股數
    --
    市值(百萬)
    5,207.24
    市盈率
    19.040
    息率
    --
    差價
    --
    52週高低
    23.400 - 15.500
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Exelixis
    證券代碼
    EXEL.US
    所屬板塊
    Biotechnology
    公司業務
    Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
    發行量
    319448174
    公司總部
    1851 Harbor Bay Parkway
    公司網址
    https://www.exelixis.com
    公司電郵
    shubbard@exelixis.com
    公司電話
    +1 650 837-7000
    暫無內容

    關於

    Exelixis(EXEL.US)所屬的行業板塊為Biotechnology。
    Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
    詳細公司背景可參考: https://www.exelixis.com